Bridget Hoyt

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression.

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Danielle Blair, RN, BSN, OCN, CCRP, explains what her role as an adolescent and young adult nurse navigator in oncology entails.

The FDA has approved the use of lisocabtagene maraleucel in patients with relapsed/refractory marginal zone lymphoma.

Catch up on recent regulatory decisions by the FDA in oncology, including actions in lung, hematologic, genitourinary, and gastrointestinal cancers.

Emily Coiro, MSN, AGACNP-BC, BMTCN; and Julie Zgola, BSN, RN, who work in stem cell transplantation, were matched with patients in need of a transplant.

The FDA has approved durvalumab plus FLOT for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Emily Shelby, MSN, FNP-C, emphasized that referrals to other specialties is key to managing heavily pretreated patients with metastatic colorectal cancer.

The FDA has approved intravenous or subcutaneous pembrolizumab combined with enfortumab vedotin-ejfv in the neoadjuvant and adjuvant MIBC settings.

Elizabeth Hubert, APRN, explains how to treat patients receiving luspatercept for low-risk myelodysplastic syndromes.

The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for the treatment of patients with HER2-positive nonsquamous non-small cell lung cancer.

The FDA granted standard approval to epcoritamab monotherapy and epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

The FDA has approved ziftomenib for relapsed or refractory acute myeloid leukemia harboring NPM1 mutations with no alternative treatment options.

Kristi Orbaugh, MSN, RNP, AOCN, AOCNP, shared the key toxicities of each CDK4/6 inhibitor and how to monitor for them.

The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj for use in patients with high-risk smoldering multiple myeloma.

An oncology APP-led quality assurance committee identified key safety events across disciplines and specialties.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

A multisite advanced practice optimization model improved patient access through tailored interventions, including redistributing non-APP responsibilities.

BCMA-targeting ADC belantamab mafodotin was approved for use in patients with relapsed/refractory multiple myeloma after 2 or more lines of treatment.

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases to become chronic.

Adding zabilugene almadenorepvec to SOC chemotherapy and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma.

A preliminary analysis of a prospective study of patients with solid tumors identified subgroups at risk of depressive symptoms via patient-report outcomes.

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment regimens, locations, and more.